drugset / Trial / NCT02125084
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never received prior chemotherapy, or who have previously received docetaxel chemotherapy and have progressive disease.
Timeline
- Start
- 2014-10
- Primary completion
- 2021-05-03
- Completion
- 2021-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Everolimus | Small molecule | — | Oral |